Navigation Links
FDA Advisers Consider Approval of Genetically Modified Salmon
Date:9/21/2010

By Jenifer Goodwin
HealthDay Reporter

TUESDAY, Sept. 21 (HealthDay News) -- U.S. Food and Drug Administration advisers continue two days of hearings Tuesday on whether to recommend approval of genetically modified salmon for humans to eat.

If the advisers recommend approval, it would mark the first time a genetically modified animal has been approved for America's dinner plates and restaurant menus. Currently, genetically modified soybeans and corn are being sold for people to eat.

The developer of the genetically modified salmon, Waltham, Mass.-based AquaBounty Technologies, believes that, if approved, the fish could help reduce pollution, disease and other problems associated with saltwater fish farms, as well as provide an alternative source of seafood to help reduce the impact of overfishing.

But opponents of approval, including many consumer advocates, worry that the fish would pose a threat to both the health of consumers and the environment.

While the FDA isn't compelled to follow the recommendations of its advisory panels, it usually does so.

On Sept. 3, a scientific panel of experts that advises the FDA paved the way for the approval of the genetically modified salmon, calling it "as safe as food from conventional Atlantic salmon."

The FDA's Veterinary Medicine Advisory Committee went on to say that the fish -- AquAdvantage Salmon developed by AquaBounty Technologies -- contained the same amount of nutrients and had "no biologically relevant differences" from ordinary farmed Atlantic salmon.

That's what worries consumer advocates, who say approving the salmon is opening the door to all sorts of genetically engineered animals, such as pigs and other mammals.

The FDA is regulating genetically engineered animals as it would a new veterinary drug, which means that much of the research and information about the product is being kept confidential, said Wenonah Hauter, executive director of Food & Water Watch in Washington, D.C.

"We don't know if it's safe for humans to eat and the only research that has been done was done by the company," according to Hauter. "The FDA is an under-resourced agency that has had so much trouble with the regulatory system for foods -- we've had tainted eggs, poisonous peanuts and other contaminations -- and is now taking on something in a very non-transparent way."

Recently, Food & Water Watch was joined by 30 other animal welfare, consumer, environmental and fisheries groups, including the Sierra Club, which issued a statement citing concerns that the fish could escape and pose an environmental threat. Previously, another group of consumer advocates and others warned that "transgenic fish" could introduce new or unknown allergens into the food supply.

AquaBounty creates its salmon by taking a growth gene from the Chinook salmon and a gene "promoter" from the ocean pout, another type of fish, said John Buchanan, AquaBounty's director of research and development. The pout gene promoter simply turns on the Chinook salmon growth gene, and is not actually "expressed" [active] in the modified fish. The resulting salmon grow to market weight about twice as fast as ordinary Atlantic salmon, though they don't get larger overall.

While it typically takes about three years for salmon to grow to market weight, AquaBounty's salmon get there in about 18 months, Buchanan said.

To safeguard the environment, Buchanan said the eggs will be treated so that all fish that grow from them will be sterile females. That means they will not be able to reproduce, nor will they come into contact with males to reproduce with, said Buchanan, whose firm would sell the treated eggs.

While farm-raised salmon are typically grown in ocean-based tanks, the genetically modified fish would be grown in land-based tanks, also minimizing the chances of escape, he said.

"We have done a tremendous amount of work geared toward regulatory approval to show that the fish is healthy and safe," Buchanan said.

Genetically modified animals have been produced since the 1970s, according to background information in the FDA's briefing materials, but none have been approved for human consumption.

AquaBounty said bringing the salmon to market would take at least 18 months after approval. Farmers who want to grow the fish would also need FDA approval of their facilities.

One question for consumers is whether packaging would be required to specify that the salmon is genetically modified. The FDA will consider that issue during the public hearings.

More information

Read what the U.S. Food and Drug Administration advisory panel had to say about genetically modified salmon.

SOURCES: Wenonah Hauter, executive director, Food & Water Watch, Washington. D.C.; John Buchanan, Ph.D., director, research and development, AquaBounty Technologies, San Diego


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Advisers Urge Stricter Regulation of Tanning Beds
2. FDA to Broaden Disclosure on Advisers Conflicts of Interest
3. FDA Advisers Say Avastin Shouldnt Be Used for Breast Cancer
4. FDA Advisers Divided on Whether to Ban Diet Drug Meridia
5. FDA Advisers Weigh Approval of Genetically Modified Salmon
6. Connecticut Board Considers Warning About Risk Of Stroke Following Chiropractic Neck Manipulation
7. Castrate-Metastatic Prostate Cancer: Therapeutic Considerations for Advanced Disease
8. Some Parents Consider Hastening a Sick Childs Death
9. MedCath Corporation Announces Decision to Consider Strategic Options
10. New clinical prediction index to help patients considering kidney transplant
11. BMI of Texas Offers Free Educational Seminars in San Antonio for People Considering Weight Loss Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Advisers Consider Approval of Genetically Modified Salmon
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... software tools that allow for the electronic prescribing of controlled and non-controlled substances ... , Ninety percent of pharmacies in the United States now accept electronic prescriptions, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's mental functions, ... each and every seminar, session and class she offers. At the International ... which help energize creativity, focus mental functions, enhance athletic focus and skill sets, ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended ... all facets of clinical trial planning and management. Pharmica discussed the importance of ... In addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
(Date:2/17/2017)... ... 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital ... the Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital ... the nation. While many providers are struggling to leverage limited resources and technology, Onslow ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, ... expected to grow at a CAGR of 9.4% from 2017-2022 and ... at a CAGR of 9.5% from 2017 to 2027. The market ... ... benefit you Read on to discover how you can exploit ...
(Date:2/17/2017)... 2017 Arvinas LLC, a private biotechnology company ... degradation, today announced the presentation of new preclinical data ... poster session at the American Society of Clinical Oncology ... Orlando, FL. "The new ... the potential of PROTACs to drive durable and robust ...
(Date:2/17/2017)... and Markets has announced the addition of the "Pharmaceutical Contract Manufacturing ... ... the US, Canada , Japan , ... of World. Annual estimates and forecasts are provided for the period 2015 ... Market data and analytics are derived from primary and secondary research. ...
Breaking Medicine Technology: